These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 24393342

  • 1. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
    Mellor HR.
    Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
    [Abstract] [Full Text] [Related]

  • 2. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
    Hagel M, Miduturu C, Sheets M, Rubin N, Weng W, Stransky N, Bifulco N, Kim JL, Hodous B, Brooijmans N, Shutes A, Winter C, Lengauer C, Kohl NE, Guzi T.
    Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
    [Abstract] [Full Text] [Related]

  • 3. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
    Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS, Loo HL, Aung MO, Lim SG, Ullrich A.
    J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
    [Abstract] [Full Text] [Related]

  • 4. FGF19-FGFR4 Signaling in Hepatocellular Carcinoma.
    Raja A, Park I, Haq F, Ahn SM.
    Cells; 2019 Jun 04; 8(6):. PubMed ID: 31167419
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation.
    Zhao H, Lv F, Liang G, Huang X, Wu G, Zhang W, Yu L, Shi L, Teng Y.
    Oncotarget; 2016 Mar 22; 7(12):13575-86. PubMed ID: 26498355
    [Abstract] [Full Text] [Related]

  • 9. The gut-liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19.
    Piglionica M, Cariello M, Moschetta A.
    Curr Opin Pharmacol; 2018 Dec 22; 43():93-98. PubMed ID: 30223181
    [Abstract] [Full Text] [Related]

  • 10. Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target.
    Liu WY, Xie DM, Zhu GQ, Huang GQ, Lin YQ, Wang LR, Shi KQ, Hu B, Braddock M, Chen YP, Zheng MH.
    Expert Opin Ther Targets; 2015 May 22; 19(5):675-85. PubMed ID: 25547779
    [Abstract] [Full Text] [Related]

  • 11. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
    Gao L, Wang X, Tang Y, Huang S, Hu CA, Teng Y.
    J Exp Clin Cancer Res; 2017 Jan 09; 36(1):8. PubMed ID: 28069043
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4.
    Chen J, Du F, Dang Y, Li X, Qian M, Feng W, Qiao C, Fan D, Nie Y, Wu K, Xia L.
    Hepatology; 2020 May 09; 71(5):1712-1731. PubMed ID: 31529503
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
    Hatlen MA, Schmidt-Kittler O, Sherwin CA, Rozsahegyi E, Rubin N, Sheets MP, Kim JL, Miduturu C, Bifulco N, Brooijmans N, Shi H, Guzi T, Boral A, Lengauer C, Dorsch M, Kim RD, Kang YK, Wolf BB, Hoeflich KP.
    Cancer Discov; 2019 Dec 09; 9(12):1686-1695. PubMed ID: 31575540
    [Abstract] [Full Text] [Related]

  • 18. H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.
    Joshi JJ, Coffey H, Corcoran E, Tsai J, Huang CL, Ichikawa K, Prajapati S, Hao MH, Bailey S, Wu J, Rimkunas V, Karr C, Subramanian V, Kumar P, MacKenzie C, Hurley R, Satoh T, Yu K, Park E, Rioux N, Kim A, Lai WG, Yu L, Zhu P, Buonamici S, Larsen N, Fekkes P, Wang J, Warmuth M, Reynolds DJ, Smith PG, Selvaraj A.
    Cancer Res; 2017 Dec 15; 77(24):6999-7013. PubMed ID: 29247039
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.